Response of Hepatitis C Genotype-4 Naive Patients to 24 Weeks of Peg-Interferon-alpha2b/Ribavirin or Induction-Dose Interferon-alpha2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study

Abstract

Response of genotype-4 patients to 24 wks of Peg-IFN-alpha2b/RBV did not significantly differ from 48 wks, but was significantly higher than IDTT. Although SVR achieved by IDTT is less than Peg-IFN-alpha, yet it might provide a second option when the latter is not affordable. Early virological response should be used as a predictor to SVR to avoid unnecessary expenses in nonresponders patients.